Carcinomas are also enriched in mutations of the oncogenic PI3K/AKT/mTOR pathway (carcinomas versus carcinoids, p = 0.0313), a potential therapeutic target to be investigated in prospective trials 10. The gene discussed is PIK3CA; the disease is carcinoid tumor.